Zymeworks

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Zymeworks and other ETFs, options, and stocks.

About ZYME

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2).

CEO

Kenneth Harry Galbraith

CEOKenneth Harry Galbraith

Employees

286

Employees286

Headquarters

Middletown, Delaware

HeadquartersMiddletown, Delaware

Founded

2003

Founded2003

Employees

286

Employees286

ZYME Key Statistics

Market cap

821.26M

Market cap821.26M

Price-Earnings ratio

-7.79

Price-Earnings ratio-7.79

Dividend yield

—

Dividend yield—

Average volume

481.73K

Average volume481.73K

High today

$11.79

High today$11.79

Low today

$11.29

Low today$11.29

Open price

$11.54

Open price$11.54

Volume

332.99K

Volume332.99K

52 Week high

$17.70

52 Week high$17.70

52 Week low

$8.21

52 Week low$8.21

Analyst ratings

78%

of 9 ratings

Buy

77.8%

Hold

22.2%

Sell

People also own

Based on the portfolios of people who own ZYME. This list is generated using Robinhood data, and it’s not a recommendation.